Latest Updates in GI Cancer
Zanzalintinib Plus Atezolizumab Improves Survival in Refractory MSS Metastatic Colorectal Cancer
Patients with refractory metastatic colorectal cancer (mCRC) and microsatellite-stable (MSS) disease have limited treatment options and historically derive minimal benefit...
From ‘Undruggable’ to Breakthrough: Pan-RAS Inhibitors Transform GI Oncology Practice
Pan-RAS inhibitors like RMC-6236 are showing unprecedented 30% response rates in previously treated pancreatic cancer, potentially ending the decades-long frustration...
PurIST® Algorithm Validated for Pancreatic Cancer First-Line Therapy Selection in Landmark Real-World Study
Real-world evidence demonstrates PurIST's ability to guide first-line treatment decisions and improve outcomes for patients.
Pan-GI Cancer Microbiota Analysis Reveals Universal Prognostic Bacterial Signatures
Fifteen bacterial genera consistently associated with prognosis across six GI tumor types, predicting survival and metastasis risk.
Targeting ‘Undruggable’ KRAS in Pancreatic Cancer: Clinical Breakthroughs and Resistance Strategies
KRASG12C inhibitors achieve 21-33% response rates with superior safety vs standard chemo in PDAC patients.
Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results
Camrelizumab plus chemoradiation improved 3-year OS to 58.2% vs 30.5% observation in resected cholangiocarcinoma/gallbladder cancer.
Latest in Bile Duct Cancer (Cholangiocarcinoma)
Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results
Camrelizumab plus chemoradiation improved 3-year OS to 58.2% vs 30.5% observation in resected cholangiocarcinoma/gallbladder cancer.
Latest in Colorectal Cancer
Zanzalintinib Plus Atezolizumab Improves Survival in Refractory MSS Metastatic Colorectal Cancer
Patients with refractory metastatic colorectal cancer (mCRC) and microsatellite-stable (MSS) disease have limited treatment options and historically derive minimal benefit...
SAKK 41/13 Trial: Adjuvant Aspirin Shows Promise in PIK3CA-Mutant Colon Cancer
First randomized trial shows aspirin 100mg daily improves disease-free survival in PIK3CA-mutant colon cancer patients.
Distinct Genomic Mutation Patterns Identified in Early-Onset Colorectal Cancer: International Multi-Cohort Analysis
EOCRC exhibited significantly higher TMB compared with LOCRC in hypermutated tumors, with distinct gene mutation patterns including elevated APC and...
Colorectal Cancer Screening Uptake Increases Following USPSTF Guidelines for Ages 45-49
CRC screening in ages 45-49 jumped from 20.8% to 33.7% post-USPSTF guidelines, but gains limited to educated, insured populations.
The Utility of Multitarget Stool DNA Testing in Community-Based Clinical Practice
MT-sDNA screening showed 0.2% CRC detection rate and 73% false-positive rate, raising questions about effectiveness in average-risk patients.
Latest in Upper GI/Gastroesophageal Cancer
From ‘Undruggable’ to Breakthrough: Pan-RAS Inhibitors Transform GI Oncology Practice
Pan-RAS inhibitors like RMC-6236 are showing unprecedented 30% response rates in previously treated pancreatic cancer, potentially ending the decades-long frustration...
Making Sense of FLOT, Durvalumab, and the Role of Real-World Tumor Biology
Total neoadjuvant therapy with FLOT may optimize outcomes, but ctDNA could guide personalized treatment decisions.
Latest in Hepatocellular Carcinoma
FDA Approves Radioembolization Therapy for Liver Cancer
Y-90 microspheres achieved 98.5% response rate and 100% local tumor control in unresectable HCC patients across multicenter trial.
Latest in Pancreatic Cancer
From ‘Undruggable’ to Breakthrough: Pan-RAS Inhibitors Transform GI Oncology Practice
Pan-RAS inhibitors like RMC-6236 are showing unprecedented 30% response rates in previously treated pancreatic cancer, potentially ending the decades-long frustration...
PurIST® Algorithm Validated for Pancreatic Cancer First-Line Therapy Selection in Landmark Real-World Study
Real-world evidence demonstrates PurIST's ability to guide first-line treatment decisions and improve outcomes for patients.
Targeting ‘Undruggable’ KRAS in Pancreatic Cancer: Clinical Breakthroughs and Resistance Strategies
KRASG12C inhibitors achieve 21-33% response rates with superior safety vs standard chemo in PDAC patients.
MicroRNA Liquid Biopsy Panel Achieves 97% Accuracy for Pancreatic Cancer Early Detection
"Even in the earlier stages of PDAC, these markers are about 91% accurate. And when we use them together with...
Latest in Gallbladder Cancer
Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results
Camrelizumab plus chemoradiation improved 3-year OS to 58.2% vs 30.5% observation in resected cholangiocarcinoma/gallbladder cancer.